Thuốc Ức chế PCSK9 trong Hội chứng mạch vành cấp: Hiện trạng và triển vọng lâm sàng

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Thanh Hương Trương

Ngôn ngữ: Vie

Ký hiệu phân loại: 612.1 Blood and circulation

Thông tin xuất bản: Tim mạch học Việt Nam 2023

Mô tả vật lý: 96-101

Bộ sưu tập: Metadata

ID: 394555

Thêm vào giỏ Liên kết toàn văn

Tóm tắt
Chủ đề

Mặc dù y học đã có nhiều tiến bộ nhưng tỷ lệ mắc bệnh và tử vong liên quan dến hội chứng mạch vành cấp tính (HCMVC) vẩn cao, đặc biệt là một năm sau biến cố cấp tính. Các nghiên cứu gần dây gợi ý liệu pháp ức chê PCSK9 có thể làm giảm đáng kể nồng độ cholesterol lipoprotein tỷ trọng thấp (LDL-C) trong huyết tương và biến cố tim mạch chính sau HCMVC nhờ tác động đến tiến triển mảng xơ vữa điều chỉnh mảng bám. Bài báo này trình bày các bằng chứng mới nhất của việc sử dụng sớm thuốc ức chê PCSK9 sau HCMVC cho tác dụng giảm mức LDL-C và biên cố tim mạch chính. Các thử nghiệm lâm sàng quan trọng như EVOPACS, ODYSSEY OUTCOMES, PACMAN-AMI và V-INCEPTION sẽ được thảo luận trong bày. Nói chung, chiên lược sử dụng sớm thuốc ức chê PCSK9 dưới dạng bổ sung cho liệu pháp statin cường độ cao trong HCMVC có vẻ là một cách tiếp cận an toàn và hiệu quả để đạt được mức LDL-C mục tiêu và giảm gánh nặng của bệnh xơ vữa động mạch., Tóm tắt tiếng anh, Despite medical advancements, morbidity and mortality rates associated with acute coronary syndrome (ACS) remain high, particularly one year after the acute event. Recent studies have shown that PCSK9 inhibitors therapy can significantly reduce plasma low-density lipoprotein cholesterol (LDL-C) levels and major adverse cardiovascular events in post-ACS patients through plaque modification. This review describes the current clinical benefits of PCSK9 inhibitors therapy early after ACS in reducing LDL-C levelsand the risk of major adverse cardiovascular events. Clinical trials such as EVOPACS, ODYSSEY OUTCOMES, PACMAN-AMI, and V-INCEPTION are discussed. In conclusion, early implementation of PCSK9 inhibitors in addition to high-intensity statins in ACS appears to be a safe and effective approach to achieving LDL-C treatment goals and reducing the burden of atherosclerotic disease.

Tạo bộ sưu tập với mã QR